FDA rejects closely watched lung cancer drug

Advertisement

The FDA has rejected Summit Therapeutics’ application for ivonescimab for certain patients with advanced lung cancer after the treatment did not show a statistically significant improvement in overall survival.

Summit said the FDA cited the finding in rejecting the drug, according to a Nov. 15 news release. The application sought approval of ivonescimab with platinum-containing chemotherapy for patients with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer who had previously received a third-generation EGFR-targeted therapy. The FDA issued a complete response letter, saying substantial evidence of effectiveness was not established without a statistically significant overall survival improvement. The agency’s decision date was Nov. 14.

The global clinical trial, called HARMONi, compared ivonescimab plus chemotherapy with chemotherapy alone. The drug delayed cancer progression, meeting one of the trial’s two primary endpoints, but the primary overall survival analysis showed a positive trend that did not reach statistical significance, Summit said. The company argues no FDA-approved regimen has shown a statistically significant survival benefit in this setting and said the lack of an overall survival result reflected slow enrollment, according to a Nov. 15 report from The New York Times. Summit sent the FDA additional analyses of longer-term outcomes that were not specified in the original research plan, but they were not enough to persuade regulators, the Times reported.

Ivonescimab, administered by intravenous infusion, combines two approaches: unleashing the immune system and depriving the tumor of a blood supply. Akeso Biopharma invented the drug and sells it in China, and Summit bought the U.S. rights. Larger drugmakers, including Merck and Pfizer, are developing medicines that take the same approach, and the drug’s supporters had hoped it could eventually compete with Merck’s Keytruda.

Ivonescimab is being tested in 17 continuing, completed or planned late-stage studies. Another trial is assessing whether the drug is better than Keytruda at prolonging lives and extending the time until cancer progresses in patients with untreated advanced lung cancer, with results expected before the end of the year, according to the Times. If it succeeds, Summit is expected to seek approval for the drug in that setting.

At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.

Advertisement

Next Up in Pharmacy

Advertisement